CopenhagenNovo Nordisk stopped two heart trials for futility.
The result undercuts a decades-old theory that cooling inflammation, not just cholesterol, prevents heart attacks.
A monitoring committee found the HERMES and ATHENA trials of ziltivekimab unlikely to succeed, following an earlier failure in the ZEUS trial.
Novo has not said whether it will pursue the inflammation approach in other diseases.
Sources: STAT